CD73: a novel checkpoint protein

STUTTGART, Germany I September 08, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active CD73 inhibitors in R&D: Pipeline of CD73 Inhibitors.

This competitive intelligence report about CD73 Inhibitors provides an up-to-date competitor evaluation in the field of antibodies, RNA and small molecules in research and development inhibiting CD73. This report will be prepared on demand within one working day upon order placement. The report lists active CD73 inhibitor R&D programs by R&D phase in a tabular format and describes in brief the profile of CD73 inhibitors by drug modality. The report will be provided in pdf format and sent by e-mail to the customer.

As an example of this category of on demand reports, please see our free sample report of “Pipeline of 5T4-Targeted Immunotherapies”.

CD73 (5’-nucleotidase or NT5E) is a cell surface enzyme which catalyzes the extracellular hydrolysis of adenosine monophosphate (AMP) to produce anti-inflammatory and immunosuppressive adenosine. Immunosupressive adenosine contributes to immune evasion in solid tumors by accumulating within the tumor microenvironment and thereby inhibiting immune effector cells (e.g., CD8⁺ T cells). As a novel checkpoint protein, CD73 is overexpressed in the immune system of various tumors, where adenosine is abundantly enriched. CD73 expression levels correlate with a worse prognosis in specific cancer types, including breast cancer. Adenosine production via CD73 can be therapeutically inhibited by two independent mechanisms: (1) enzyme inhibition, and (2) receptor internalization and subsequent degradation. The reduction of adenosine restores immune function. Once the immunosuppressive effects of adenosine are removed, activation of antitumor immune cells may be restored resulting in tumor cell death.

A large number of monoclonal antibodies (mAbs), nucleotides, and non-nucleotides as potent CD73 inhibitors are being discovered, providing opportunities for novel tumor immunotherapy. CD73 inhibitors in clinical trials show promising results in combination therapy for various solid tumors. The development of CD73-specific companion positron emission tomography imaging ligands holds potential for facilitating diagnosis, patient selection, and treatment efficacy evaluation throughout the entire process of CD73-targeted therapeutic development.

The report “Pipeline of CD73 Inhibitors” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/pipeline-of-cd73-inhibitors/

About La Merie Publishing

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.

La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, customized reports about target evaluation, pipeline analysis, technology assessments, drug and competitor profiles, partnering and business deal terms and any other competitive intelligence elaboration of interest.

Among La Merie Publishing’s services are the pre-scoped evaluation of customer-selected targets for drug discovery: Target Evaluation for Drug Discovery: Pre-Scoped Premium Evaluation and the pre-scoped review of the pipeline of immunotherapies against customer-selected targets: Pipeline Review of Customer-Selected Targeted Immunotherapies: Pre-Scoped Competitor Analysis.

SOURCE: La Merie Publishing